15 results on '"Bonthuis, Marjolein"'
Search Results
2. Growth in children on kidney replacement therapy: a review of data from patient registries
- Author
-
Bonthuis, Marjolein, Harambat, Jérôme, Jager, Kitty J., and Vidal, Enrico
- Published
- 2021
- Full Text
- View/download PDF
3. The ERA Registry Annual Report 2021: a summary.
- Author
-
Boerstra, Brittany A, Boenink, Rianne, Astley, Megan E, Bonthuis, Marjolein, ElHafeez, Samar Abd, Monzón, Federico Arribas, Åsberg, Anders, Beckerman, Pazit, Bell, Samira, Amenós, Aleix Cases, Nuez, Pablo Castro de la, Dam, Marc A G J ten, Debska-Slizien, Alicja, Gjorgjievski, Nikola, Giudotti, Rebecca, Helve, Jaakko, Hommel, Kristine, Idrizi, Alma, Indriðason, Ólafur S, and Jarraya, Faiçal
- Subjects
CORPORATION reports ,RENAL replacement therapy ,CHRONIC kidney failure ,KIDNEY transplantation ,PERITONEAL dialysis ,IGA glomerulonephritis - Abstract
Background The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper is a summary of the ERA Registry Annual Report 2021, including a comparison across treatment modalities. Methods Data was collected from 54 national and regional registries from 36 countries, of which 35 registries from 18 countries contributed individual patient data and 19 registries from 19 countries contributed aggregated data. Using this data, incidence and prevalence of KRT, kidney transplantation rates, survival probabilities and expected remaining lifetimes were calculated. Result In 2021, 533.2 million people in the general population were covered by the ERA Registry. The incidence of KRT was 145 per million population (pmp). In incident patients, 55% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes (22%). The prevalence of KRT was 1040 pmp. In prevalent patients, 47% were 65 years or older, 62% were male, and the most common PRDs were diabetes and glomerulonephritis/sclerosis (both 16%). On 31 December 2021, 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. The kidney transplantation rate in 2021 was 37 pmp, a majority coming from deceased donors (66%). For patients initiating KRT between 2012–2016, 5-year survival probability was 52%. Compared to the general population, life expectancy was 65% and 68% shorter for males and females receiving dialysis, and 40% and 43% shorter for males and females living with a functioning graft. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Outcomes of renal replacement therapy in boys with prune belly syndrome: findings from the ESPN/ERA-EDTA Registry
- Author
-
Yalcinkaya, Fatos, Bonthuis, Marjolein, Erdogan, Beyza Doganay, van Stralen, Karlijn J., Baiko, Sergey, Chehade, Hassib, Maxwell, Heather, Montini, Giovanni, Rönnholm, Kai, Sørensen, Søren Schwartz, Ulinski, Tim, Verrina, Enrico, Weber, Stefanie, Harambat, Jérôme, Schaefer, Franz, Jager, Kitty J., and Groothoff, Jaap W.
- Published
- 2017
- Full Text
- View/download PDF
5. Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry
- Author
-
Hölttä, Tuula, Bonthuis, Marjolein, Van Stralen, Karlijn J., Bjerre, Anna, Topaloglu, Rezan, Ozaltin, Fatih, Holmberg, Christer, Harambat, Jerome, Jager, Kitty J., Schaefer, Franz, and Groothoff, Jaap W.
- Published
- 2016
- Full Text
- View/download PDF
6. The ERA Registry Annual Report 2019: summary and age comparisons
- Author
-
Boenink, Rianne, Astley, Megan E., Huijben, Jilske A., Stel, Vianda S., Kerschbaum, Julia, Ots-Rosenberg, Mai, Åsberg, Anders A., Lopot, Frantisek, Golan, Eliezer, Castro de la Nuez, Pablo, Rodríguez Camblor, Marta, Trujillo-Alemán, Sara, Ruiz San Millan, Juan Carlos, Ucio Mingo, Pablo, Díaz Gómez, Juan Manuel, Bouzas-Caamaño, M. Encarnación, Artamendi, Marta, Aparicio Madre, Manuel I, Santiuste de Pablos, Carmen, Slon Roblero, María Fernanda, Zurriaga, Oscar, Stendahl, Maria E., Bell, Samira, Idrizi, Alma, Ioannou, Kyriakos, Debska-Slizien, Alicja, Galvão, Ana A., De Meester, Johan, Resić, Halima, Hommel, Kristine, Radunovic, Danilo, Pálsson, Runolfur, Lassalle, Mathilde, Finne, Patrik, Garcia Bazaga, María De los Ángeles, Gjorgjievski, Nikola, Seyahi, Nurhan, Bonthuis, Marjolein, Ortiz, Alberto, Jager, Kitty J., Kramer, Anneke, Universitat Autònoma de Barcelona, Department of Medicine, Clinicum, Nefrologian yksikkö, Helsinki University Hospital Area, Graduate School, Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Methodology, APH - Health Behaviors & Chronic Diseases, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, and UAM. Departamento de Medicina
- Subjects
Transplantation ,patient survival ,Medicina ,Nephrology ,3121 General medicine, internal medicine and other clinical medicine ,graft survival ,dialysis ,kidney transplantation ,epidemiology ,ESRD ,3126 Surgery, anesthesiology, intensive care, radiology - Abstract
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAM, Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons. Methods: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated. In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities, The ERA Registry is funded by the ERA. This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, S.B. reports personal fees from AstraZeneca, outside the submitted work; A.D.-S. reports personal fees from Astellas and Fresenius, outside the submitted work; F.L. reports personal fees from MeditesPharma, outside the submitted work; R.P. reports grants from The Iceland Centre for Research, Landspitali University Hospital Research Fund and University of Iceland Research Fund, outside the submitted work; P.F. reports grants from Finska läkaresällskapet and Liv och Hälsa, outside the submitted work; M.F.S.R. reports personal fees from Baxter and Fresenius, outside the submitted work; A.O. reports grants from Sanofi, and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical Care and Idorsia, outside the submitted work; and K.J.J. reports grants from ERA, during the conduct of the study
- Published
- 2022
7. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease
- Author
-
Drube, Jens, Wan, Mandy, Bonthuis, Marjolein, Wuhl, Elke, Bacchetta, Justine, Santos, Fernando, Grenda, Ryszard, Edefonti, Alberto, Harambat, Jerome, Shroff, Rukshana, Tonshoff, Burkhard, Haffner, Dieter, Schnabel, D, Linglart, A, Rees, L, Cochat, P, Brauner, C, Renault, D, Romano, LN, Colling, G, Prytula, A, Leifheit-Nestler, M, Klaus, G, Schmitt, CP, Stabouli, S, Reusz, G, Verrina, E, Groothoff, J, Anton-Gamero, M, Petrosyan, E, Bakkaloglu, SA, Dursun, I, Booth, C, Aufricht, C, Vande Walle, J, Vondrak, K, Holtta, T, Ranchin, B, Fischbach, M, Stefanidis, C, Kyriakou, A, Printza, N, Paglialonga, F, Vidal, E, Allinovi, M, Jankauskiene, A, Zurowska, A, Faria, M Do Sameiro, Ariceta, G, Sartz, L, Bakkaloglu, S, Bayazit, AK, Duzova, A, Knops, N, Raees, A, Zieg, J, Pape, L, Melk, A, Dello, L, Guzzo, I, Ghio, L, Murer, L, Peruzzi, L, Bouts, A, Cornelissen, M, Lopez-Baez, Victor, Soylemezoglu, O, Topaloglu, R, Christian, M, Marks, S, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinicum, HUS Children and Adolescents, Helsinki University Hospital Area, Lastentautien yksikkö, Children's Hospital, and Çukurova Üniversitesi
- Subjects
0301 basic medicine ,PREPUBERTAL CHILDREN ,Pediatrics ,medicine.medical_treatment ,030232 urology & nephrology ,Growth disorders ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,0302 clinical medicine ,Quality of life ,QUALITY-OF-LIFE ,3123 Gynaecology and paediatrics ,Chronic kidney disease ,Child ,ADULT HEIGHT ,Human Growth Hormone ,Immunosuppression ,Urology & Nephrology ,DOUBLE-BLIND TRIAL ,3. Good health ,Growth hormone treatment ,Nephrology ,Child, Preschool ,medicine.symptom ,Life Sciences & Biomedicine ,medicine.medical_specialty ,CATCH-UP GROWTH ,Short stature ,03 medical and health sciences ,REPLACEMENT THERAPY ,Renal Dialysis ,medicine ,Humans ,Renal Insufficiency, Chronic ,SHORT STATURE ,Dialysis ,LONG-TERM GROWTH ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Science & Technology ,Paediatric kidney disease ,PEDIATRIC-PATIENTS ,business.industry ,Consensus Statement ,Guideline ,medicine.disease ,3126 Surgery, anesthesiology, intensive care, radiology ,Kidney Transplantation ,Hormones ,Transplantation ,030104 developmental biology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,CHRONIC-RENAL-FAILURE ,business ,Kidney disease - Abstract
Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD and short stature to reach normal adult height. Here, members of the European Society for Paediatric Nephrology (ESPN) CKD–Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clinical practice recommendations for the use of GH in children with CKD on dialysis and after renal transplantation. These recommendations have been developed with input from an external advisory group of paediatric endocrinologists, paediatric nephrologists and patient representatives. We recommend that children with stage 3–5 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defined as a height below the third percentile for age and sex and a height velocity below the twenty-fifth percentile, once other potentially treatable risk factors for growth failure have been adequately addressed and provided the child has growth potential. In children who have received a kidney transplant and fulfil the above growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous catch-up growth does not occur and steroid-free immunosuppression is not a feasible option. GH should be given at dosages of 0.045–0.05 mg/kg per day by daily subcutaneous injections until the patient has reached their final height or until renal transplantation. In addition to providing treatment recommendations, a cost-effectiveness analysis is provided that might help guide decision-making., This Evidence-Based Guideline developed by members of the European Society for Paediatric Nephrology CKD-MBD, Dialysis and Transplantation working groups presents clinical practice recommendations for the use of growth hormone in children with chronic kidney disease on dialysis and after renal transplantation.
- Published
- 2019
8. The ERA-EDTA Registry Annual Report 2017: a summary.
- Author
-
Kramer, Anneke, Boenink, Rianne, Noordzij, Marlies, Bosdriesz, Jizzo R, Stel, Vianda S, Beltrán, Palma, Ruiz, Juan C, Seyahi, Nurhan, Farnés, Jordi Comas, Stendahl, Maria, Garneata, Liliana, Winzeler, Rebecca, Golan, Eliezer, Lopot, František, Korejwo, Grzegorz, Bonthuis, Marjolein, Lassalle, Mathilde, Roblero, Maria F Slon, Kuzema, Viktorija, and Hommel, Kristine
- Subjects
CHRONIC kidney failure ,HEMODIALYSIS patients ,KIDNEY transplantation ,HEMODIALYSIS ,KIDNEY diseases - Abstract
Background This article presents a summary of the 2017 Annual Report of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry and describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 37 countries. Methods The ERA-EDTA Registry received individual patient data on patients undergoing RRT for ESRD in 2017 from 32 national or regional renal registries and aggregated data from 21 registries. The incidence and prevalence of RRT, kidney transplantation activity and survival probabilities of these patients were calculated. Results In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were men, 52% were ≥65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008–12, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary.
- Author
-
Kramer, Anneke, Pippias, Maria, Noordzij, Marlies, Stel, Vianda S, Andrusev, Anton M, Aparicio-Madre, Manuel I, Monzón, Federico E Arribas, Åsberg, Anders, Barbullushi, Myftar, Beltrán, Palma, Bonthuis, Marjolein, Caskey, Fergus J, Nuez, Pablo Castro de la, Cernevskis, Harijs, Meester, Johan De, Finne, Patrik, Golan, Eliezer, Heaf, James G, Hemmelder, Marc H, and Ioannou, Kyriakos
- Abstract
Background This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries. Methods In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52 national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data. The incidence and prevalence of RRT and the survival probabilities of these patients were determined. Results In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to 251 pmp in Greece. Almost two-thirds of patients were men, over half were aged ≥65 years and almost a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2007–11, the 5-year unadjusted patient survival probability on all RRT modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and 1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007–11, the adjusted patient survival probabilities appeared to be higher for women than for men. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary.
- Author
-
Kramer, Anneke, Pippias, Maria, Noordzij, Marlies, Stel, Vianda S, Afentakis, Nikolaos, Ambühl, Patrice M, Andrusev, Anton M, Fuster, Emma Arcos, Monzón, Federico E Arribas, Åsberg, Anders, Barbullushi, Myftar, Bonthuis, Marjolein, Caskey, Fergus J, Nuez, Pablo Castro de la, Cernevskis, Harijs, Grottes, Jean-Marin des, Garneata, Liliana, Golan, Eliezer, Hemmelder, Marc H, and Ioannou, Kyriakos
- Subjects
KIDNEY transplantation ,HEMODIALYSIS ,MEDICAL registries - Abstract
Background: This article summarizes the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry's 2015 Annual Report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2015 within 36 countries. Methods: In 2016 and 2017, the ERA-EDTA Registry received data on patients who were undergoing RRT for ESRD in 2015, from 52 national or regional renal registries. Thirty-two registries provided individual patient-level data and 20 provided aggregated-level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2015, 81 373 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 119 per million population (pmp). The incidence ranged by 10-fold, from 24 pmp in Ukraine to 232 pmp in the Czech Republic. Of the patients commencing RRT, almost two-thirds were men, over half were aged≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 85% of the patients, peritoneal dialysis for 11% and a kidney transplant for 4%. By Day 91 of commencing RRT, 82% of patients were receiving haemodialysis, 13% peritoneal dialysis and 5% had a kidney transplant. On 31 December 2015, 546 783 individuals were receiving RRT for ESRD, corresponding to an unadjusted prevalence of 801 pmp. This ranged throughout Europe by more than 10-fold, from 178 pmp in Ukraine to 1824 pmp in Portugal. In 2015, 21 056 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 31 pmp. This varied from 2 pmp in Ukraine to 94 pmp in the Spanish region of Cantabria. For patients commencing RRT during 2006-10, the 5-year unadjusted patient survival probabilities on all RRT modalities combined was 50.0% (95% confidence interval 49.9-50.1). [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Outcomes of renal replacement therapy in boys with prune belly syndrome: findings from the ESPN/ERA-EDTA Registry.
- Author
-
Yalcinkaya, Fatos, Bonthuis, Marjolein, Erdogan, Beyza Doganay, van Stralen, Karlijn J., Baiko, Sergey, Chehade, Hassib, Maxwell, Heather, Montini, Giovanni, Rönnholm, Kai, Sørensen, Søren Schwartz, Ulinski, Tim, Verrina, Enrico, Weber, Stefanie, Harambat, Jérôme, Schaefer, Franz, Jager, Kitty J., and Groothoff, Jaap W.
- Subjects
- *
TREATMENT effectiveness , *PRUNE belly syndrome , *REPORTING of diseases , *HEMODIALYSIS , *KIDNEY diseases , *PEDIATRICS , *TIME , *TRANSPLANTATION of organs, tissues, etc. , *THERAPEUTICS - Abstract
Background: As outcome data for prune belly syndrome (PBS) complicated by end-stage renal disease are scarce, we analyzed characteristics and outcomes of children with PBS using the European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry data. Methods: Data were available for 88 male PBS patients aged <20 years who started renal replacement therapy (RRT) between 1990 and 2013 in 35 European countries. Patient characteristics, survival, and transplantation outcomes were compared with those of male patients requiring RRT due to congenital obstructive uropathy (COU) and renal hypoplasia or dysplasia (RHD). Results: Median age at onset of RRT in PBS was lower [7.0; interquartile range (IQR) 0.9-12.2 years] than in COU (9.6; IQR: 3.0-14.1 years) and RHD (9.4; IQR: 2.7-14.2 years). Unadjusted 10-year patient survival was 85% for PBS, 94% for COU, and 91% for RHD. After adjustment for country, period, and age, PBS mortality was similar to that of RHD but higher compared with COU [hazard ratio (HR) 1.96, 95% confidence interval (CI) 1.03-3.74]. Seventy-four PBS patients (84%) received a first kidney transplant after a median time on dialysis of 8.4 (IQR 0.0-21.1) months. Outcomes with respect to time on dialysis before transplantation, chance of receiving a first transplant within 2 years after commencing RRT, and death-censored, adjusted risk of graft loss were similar for all groups. Conclusions: This study in the largest cohort of male patients with PBS receiving RRT to date demonstrates that outcomes are comparable with other congenital anomalies of the kidney and urinary tract, except for a slightly higher mortality risk compared with patients with COU. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Racial variation in cardiovascular disease risk factors among European children on renal replacement therapy--results from the European Society for Paediatric Nephrology/European Renal Association - European Dialysis and Transplant Association Registry.
- Author
-
Tjaden, Lidwien A., Jager, Kitty J., Bonthuis, Marjolein, Kuehni, Claudia E., Lilien, Marc R., Seeman, Tomas, Stefanidis, Constantinos J., Tse, Yincent, Harambat, Jérôme, Groothoff, Jaap W., and Noordzij, Marlies
- Subjects
CARDIOVASCULAR diseases risk factors ,KIDNEY transplantation ,JUVENILE diseases ,DISEASE prevalence - Abstract
Background. Racial differences in overall mortality rates have been found in children on renal replacement therapy (RRT).We used data from the European Society for Paediatric Nephrology/European Renal Association - European Dialysis and Transplant Association Registry to study racial variation in the prevalence of cardiovascular disease (CVD) risk factors among European children on RRT. Methods. We included patients aged<20 years between 2006-13 who (i) initiated dialysis treatment or (ii) had a renal transplant vintage of1 year. Racial groups were defined as white, black, Asian and other. The CVD risk factors assessed included uncontrolled hypertension, obesity, hyperphosphataemia and anaemia. Differences between racial groups in CVD risk factors were examined using generalized estimating equation (GEE) models while adjusting for potential confounders. Results. In this study, 1161 patients on dialysis and 1663 patients with a transplant were included. The majority of patients in both groups were white (73.8% and 79.9%, respectively). The crude prevalence of the CVD risk factors was similar across racial groups. However, after adjustment for potential confounders, Asian background was associated with higher risk of uncontrolled hypertension both in the dialysis group [odds ratio (OR): 1.27; 95% confidence interval (CI): 1.01-1.64] and the transplant group (OR: 1.37; 95% CI: 1.11-1.68) compared with white patients. Patients of Asian and other racial background with a renal transplant had a higher risk of anaemia compared with white patients (OR: 1.50; 95% CI: 1.15-1.96 and OR: 1.45; 95% CI: 1.01-2.07, respectively). Finally, the mean number of CVD risk factors among dialysis patients was higher in Asian patients (1.83, 95% CI: 1.64-2.04) compared with white patients (1.52, 95% CI: 1.40-1.65). Conclusions. We found a higher prevalence of modifiable CVD risk factors in Asian children on RRT. Early identification and management of these risk factors could potentially improve long-term outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. The European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2014: a summary.
- Author
-
Pippias, Maria, Kramer, Anneke, Noordzij, Marlies, Afentakis, Nikolaos, de la Torre, Ramón Alonso, Ambühl, Patrice M., Aparicio Madre, Manuel I., Monzón, Felipe Arribas, Åsberg, Anders, Bonthuis, Marjolein, Caamaño, Encarnación Bouzas, Bubic, Ivan, Caskey, Fergus J., de la Nuez, Pablo Castro, Cernevskis, Harijs, Garcia Bazaga, Maria de los Ángeles, des Grottes, Jean-Marin, Fernández González, Raquel, Ferrer-Alamar, Manuel, and Finne, Patrik
- Subjects
HEMODIALYSIS ,KIDNEY disease treatments ,EPIDEMIOLOGY ,KIDNEY transplantation ,KIDNEY disease diagnosis - Abstract
Background: This article summarizes the European Renal Association - European Dialysis and Transplant Association Registry's 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2014 within 35 countries. Methods: In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51 national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated patient level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31 December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp. This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014,19 406 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied considerably throughout Europe. For patients commencing RRT during 2005-09, the 5-year-adjusted patient survival probabilities on all RRT modalities was 63.3% (95% confidence interval 63.0-63.6). The expected remaining lifetime of a 20- to 24- year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Dyslipidaemia in children on renal replacement therapy.
- Author
-
Bonthuis, Marjolein, van Stralen, Karlijn J., Jager, Kitty J., Baiko, Sergey, Jahnukainen, Timo, Laube, Guido F., Podracka, Ludmila, Seeman, Tomás, Tyerman, Kay, Ulinski, Tim, Groothoff, Jaap W., Schaefer, Franz, and Verrina, Enrico
- Subjects
- *
DYSLIPIDEMIA , *KIDNEY transplantation , *PERITONEAL dialysis , *CYCLOSPORINS , *DISEASE prevalence , *LIPIDS , *HOMOGRAFTS - Abstract
Background Information on lipid abnormalities in end-stage renal disease (ESRD) mainly originates from adult patients and small paediatric studies. We describe the prevalence of dyslipidaemia, and potential determinants associated with lipid measures in a large cohort of paediatric ESRD patients. Methods In the ESPN/ERA-EDTA registry, lipid measurements were available for 976 patients aged 2–17 years from 19 different countries from the year 2000 onwards. Dyslipidaemia was defined as triglycerides >100 mg/dL (2–9 years) or >130 mg/dL (9–17 years), high-density lipoprotein (HDL) cholesterol <40 mg/dL or non-HDL cholesterol >145 mg/dL. Missing data were supplemented using multiple imputation. Results The prevalence of dyslipidaemia was 85.1% in peritoneal dialysis (PD) patients, 76.1% in haemodialysis (HD) patients and 55.5% among renal allograft recipients. Both low and high body mass index (BMI) were associated with a less favourable lipid profile. Younger age was associated with a worse lipid profile among PD patients. HDL levels significantly improved after transplantation, whereas no significant improvements were found for triglyceride and non-HDL levels. In transplant recipients, use of cyclosporin was associated with significantly higher non-HDL and HDL levels than tacrolimus usage (P < 0.01). In transplant patients with eGFR < 29 mL/min/1.73 m2, the mean triglyceride level was 137 mg/dL (99% confidence interval (CI): 119–159) compared with 102 mg/dL among those with eGFR > 90 mL/min/1.73 m2 (P < 0.0001). Conclusions Dyslipidaemia is common among paediatric ESRD patients in Europe. Young age and PD treatment are associated with worse lipid profiles. Although lipid levels generally improve after transplantation, dyslipidaemia may persist due to decreased graft function, high BMI or to the use of certain immunosuppressants. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
15. Infants Requiring Maintenance Dialysis: Outcomes of Hemodialysis and Peritoneal Dialysis
- Author
-
K. van Hoeck, Khadizha Emirova, Karlijn J. van Stralen, J.M. des Grottes, G. von Gersdorff, Kitty J. Jager, C. Afonso, O. Berbeca, Vidar O. Edvardsson, Diamant Shtiza, D. Roussinov, L. Backmän, Jadranka Buturović-Ponikvar, Polina Miteva, Stefano Picca, Tamás Szabó, Anastasios Kapogiannis, Paloma Maria Parvex, Staffan Schön, B. Rippe, Ludmila Podracka, Conceição Mota, Aleksandra Zurowska, Ilona Zagozdzon, Sibylle Tschumi, S. Gatcan, Mirjana Kostic, Gordana Milosevski-Lomic, Enrico Vidal, Natalia Tomilina, N. Abazi, Valerie Said-Conti, Guido F. Laube, Ana Sánchez-Moreno, Runolfur Palsson, Marjolein Bonthuis, A. Cassula, Dusan Paripovic, Brigitte Adams, A. Sukalo, Anna Bjerre, A. Alonso Melgar, S. Puric, Jérôme Harambat, D. Pokrajac, Antal Szabó, N. Zaikova, Aysun Karabay Bayazit, Frederic Collart, Cécile Couchoud, Aline C. Hemke, Boris Bikbov, B. Höcker, Nina Battelino, Karel Vondrak, S. Rudaitis, D. Batinić, Carmine Pecoraro, F. Braddon, Gabriel Mircescu, M. Lemac, Marie Evans, Brankica Spasojević-Dimitrijeva, N. Ristoka Bojkovska, Sergey Baiko, Torbjørn Leivestad, Silvio Maringhini, C.E. Kuenhi, R. Pruthi, Christoph J. Mache, S. Mannings, Franz Schaefer, Andries J. Hoitsma, Elisabeth Maurer, Tomáš Seeman, Gregor Novljan, Augustina Jankauskiene, Enrico Verrina, Rezan Topaloglu, José Eduardo Esteves Da Silva, Antonella Trivelli, R. Oberbauer, Lars Pape, Nikolaos Afentakis, Bruno Gianoglio, M. Lasalle, K. Krupka, Nicholas C. Chesnaye, Gabriel Kolvek, Jaap W. Groothoff, Christer Holmberg, Nikoleta Printza, James G. Heaf, Eva Kis, S. Pavićević, Patrik Finne, C. Scholz, Maria Stendahl, Divna Kruscic, C.S. Berecki, Manish D. Sinha, Carola Grönhagen-Riska, J. Slavicek, Z.S. Györke, Amira Peco-Antic, Emilija Sahpazova, M. Almeida, Burkhard Tönshoff, Karl G. Prütz, G Reusz, Elena A. Molchanova, D. Ivanov, Maria Herthelius, Reinhard Kramar, Sara Testa, U. Toots, Liliana Garneata, University of Zurich, Bonthuis, Marjolein, Clinicum, Children's Hospital, Lastentautien yksikkö, University of Helsinki, HUS Children and Adolescents, and Çukurova Üniversitesi
- Subjects
CHRONIC KIDNEY-DISEASE ,Ischemia/complications ,Male ,Time Factors ,genetic structures ,Hemolytic-Uremic Syndrome/complications ,Peritoneal Dialysis/methods ,medicine.medical_treatment ,030232 urology & nephrology ,CHILDREN ,Chronic/etiology/therapy ,Health Services Accessibility ,Kidney Failure ,0302 clinical medicine ,Glomerulonephritis ,3123 Gynaecology and paediatrics ,Ischemia ,Vasculitis/complications ,Cause of Death ,Medicine ,ESPN/ERA-EDTA Registry ,Registries ,European Registery for Children on Renal Replacement Therapy ,Kidney transplantation ,ddc:618 ,2727 Nephrology ,STAGE RENAL-DISEASE ,Age Factors ,Kidney Diseases, Cystic ,3. Good health ,Europe ,Survival Rate ,Treatment Outcome ,Renal Dialysis/methods ,Nephrology ,Pediatric nephrology ,SURVIVAL ,outcome ,Kidney Diseases ,Median body ,Female ,Hemodialysis ,Peritoneal Dialysis ,psychological phenomena and processes ,Vasculitis ,Glomerulonephritis/complications ,medicine.medical_specialty ,610 Medicine & health ,hemodialysis (HD) ,survival ,Urogenital Abnormalities/complications ,maintenance dialysis ,Peritoneal dialysis ,REPLACEMENT THERAPY ,03 medical and health sciences ,AGE ,Metabolic Diseases ,Renal Dialysis ,030225 pediatrics ,Internal medicine ,MANAGEMENT ,otorhinolaryngologic diseases ,Humans ,RRT modality ,end-stage renal disease (ESRD) ,infant ,peritoneal dialysis (PD) ,renal replacement therapy (RRT) ,Mortality ,Survival rate ,Dialysis ,Proportional Hazards Models ,Retrospective Studies ,TRANSPLANTATION ,business.industry ,1ST YEAR ,Infant, Newborn ,Infant ,Metabolic Diseases/complications ,Newborn ,medicine.disease ,Kidney Transplantation ,Surgery ,Transplantation ,10036 Medical Clinic ,3121 General medicine, internal medicine and other clinical medicine ,Urogenital Abnormalities ,Kidney Transplantation/statistics & numerical data ,Hemolytic-Uremic Syndrome ,Cystic/complications ,EXPERIENCE ,Kidney Failure, Chronic ,business ,Kidney disease - Abstract
Background: The impact of different dialysis modalities on clinical outcomes has not been explored in young infants with chronic kidney failure. Study Design: Cohort study. Setting & Participants: Data were extracted from the ESPN/ERA-EDTA Registry. This analysis included 1,063 infants 12 months or younger who initiated dialysis therapy in 1991 to 2013. Factor: Type of dialysis modality. Outcomes & Measurements: Differences between infants treated with peritoneal dialysis (PD) or hemodialysis (HD) in patient survival, technique survival, and access to kidney transplantation were examined using Cox regression analysis while adjusting for age at dialysis therapy initiation, sex, underlying kidney disease, and country of residence. Results: 917 infants initiated dialysis therapy on PD, and 146, on HD. Median age at dialysis therapy initiation was 4.5 (IQR, 0.7-7.9) months, and median body weight was 5.7 (IQR, 3.7-7.5) kg. Although the groups were homogeneous regarding age and sex, infants treated with PD more often had congenital anomalies of the kidney and urinary tract (CAKUT; 48% vs 27%), whereas those on HD therapy more frequently had metabolic disorders (12% vs 4%). Risk factors for death were younger age at dialysis therapy initiation (HR per each 1-month later initiation, 0.95; 95% CI, 0.90-0.97) and non-CAKUT cause of chronic kidney failure (HR, 1.49; 95% CI, 1.08-2.04). Mortality risk and likelihood of transplantation were equal in PD and HD patients, whereas HD patients had a higher risk for changing dialysis treatment (adjusted HR, 1.64; 95% CI, 1.17-2.31). Limitations: Inability to control for unmeasured confounders not included in the Registry database and missing data (ie, comorbid conditions). Low statistical power because of relatively small number of participants. Conclusions: Despite a widespread preconception that HD should be reserved for cases in which PD is not feasible, in Europe, we found 1 in 8 infants in need of maintenance dialysis to be initiated on HD therapy. Patient characteristics at dialysis therapy initiation, prospective survival, and time to transplantation were very similar for infants initiated on PD or HD therapy. (C) 2016 by the National Kidney Foundation, Inc.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.